Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Capitalizing on apolipoprotein trafficking to deliver mRNA to the brain

Project description

Cracking the brain’s barrier with smart mRNA delivery

Getting treatments into the brain is one of medicine’s toughest puzzles. The blood-brain barrier (BBB) is a tightly controlled wall of cells. It shields our brains but also blocks many promising drugs. Supported by the Marie Skłodowska-Curie Actions programme, the PORTAL project is taking a fresh approach, inspired by the body’s own delivery system: apolipoproteins. These natural nanoparticles can cross the BBB. PORTAL is testing 400 apolipoprotein-based nanoparticles to find the best at delivering mRNA to brain cells in a model of neuroinflammation. Each one carries genetic barcodes to track its journey. By blending bioengineering and nanotech, PORTAL could pave the way for new mRNA therapies for brain disorders.

Objective

Efficient therapeutic delivery across the blood-brain barrier (BBB) remains a significant challenge in treating neurological disorders. The BBB, composed of tightly regulated endothelial cells, severely restricts drug access to the brain, reducing efficacy and increasing off-target effects. While lipid nanoparticles (LNPs) have been essential for developing mRNA-based vaccines, their use in brain-targeted therapies is limited by poor BBB penetration and suboptimal mRNA translation.
Apolipoproteins, our body’s own nanodelivery system, possess the inherent ability to cross the BBB. Extensive preliminary data demonstrate that apolipoprotein nanoparticles (aNPs) efficiently integrate mRNA for extrahepatic delivery and are a compelling platform for brain targeting. While mRNA immune cell delivery firmly established, I propose exploring apolipoprotein nanoparticles (aNPs) for mRNA delivery to the brain.
The PORTAL project aims to harness the unique properties of apolipoproteins to deliver mRNA across the BBB. By screening 400 compositionally diverse aNPs—comprising apolipoprotein A1, E, and fusion apolipoproteins targeting BBB receptors—this project seeks to identify lead candidates for effective mRNA delivery to the brain. Each aNP will carry mRNA encoding Cre recombinase, along with unique DNA barcodes for detailed biodistribution and functional studies in the A14 neuroinflammation mouse model.
By integrating protein engineering, RNA therapeutics, and preclinical neuroinflammation models, this research aims to uncover key factors driving BBB penetration and mRNA delivery efficiency. The innovative combination of apolipoproteins and lipid nanotechnology will unlock new pathways to the brain, setting a new standard for RNA-based treatments. Upon completion of this Program, I will be equipped with cutting-edge technical, teaching, and leadership skills, empowering me to excel as an independent researcher and drive innovation of nanomedicine brain treatments.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

TECHNISCHE UNIVERSITEIT EINDHOVEN
Net EU contribution
€ 217 076,16
Address
GROENE LOPER 3
5612 AE Eindhoven
Netherlands
Region
Zuid-Nederland Noord-Brabant Zuidoost-Noord-Brabant
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)